๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Ultrasound of transitional cell carcinoma

โœ Scribed by Paul D. Ostrovsky; Linda Cam; Joan Goodman


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
403 KB
Volume
13
Category
Article
ISSN
0091-2751

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Transitional cell carcinoma of the endom
โœ Ruth A. Lininger; Raheela Ashfaq; Jorge Albores-Saavedra; Fattaneh A. Tavassoli ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 678 KB

amount. Immunostaining for cytokeratins 7 and 20 was performed. of Texas Southwestern Medical Center, Dallas, RESULTS. Among the 8 women with primary endometrial tumors, the mean age Texas. was 61.6 years (range, 41-83 years). Uterine bleeding was the presenting symptom in 7 women. Macroscopically,

Transitional cell carcinoma of the prost
โœ Arnold B. Rubenstein; Myron E. Rubnitz ๐Ÿ“‚ Article ๐Ÿ“… 1969 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 448 KB ๐Ÿ‘ 3 views
Transitional cell carcinoma in an ileal
โœ Thomas K. Rosvanis; Thomas J. Rohner; Arthur B. Abt ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 370 KB ๐Ÿ‘ 2 views
Urinary biomarker profiling in transitio
โœ Nicholas P. Munro; David A. Cairns; Paul Clarke; Mark Rogers; Anthea J. Stanley; ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 262 KB

## Abstract Urinary biomarkers or profiles that allow noninvasive detection of recurrent transitional cell carcinoma (TCC) of the bladder are urgently needed. We obtained duplicate proteomic (SELDI) profiles from 227 subjects (118 TCC, 77 healthy controls and 32 controls with benign urological cond

Systemic chemotherapy of transitional ce
โœ William M. Brinkley; Frank M. Torti ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 62 KB ๐Ÿ‘ 3 views

Although the incidence of bladder cancer has increased in recent years, survival has also improved. Chemotherapy has made a substantial impact on this disease and now is used in patients with advanced or metastatic disease as well as in select patients with high-risk muscle invasive disease. While c